Skip to main content
. 2016 Dec 22;11:23–31. doi: 10.2147/PPA.S118589

Table 2.

Clinical characteristics of patients included in the study (n=219)

Variable All patients
(n=219)
Low HRQOL
(n=111)
High HRQOL
(n=108)
P-value
CD, n (%) 146 (66.7) 76 (68.5) 70 (64.8) 0.566
Active disease, n (%) 56 (25.6) 46 (41.4) 10 (9.3) <0.001
HBI (CD, n=146), median (range) 2.0 (0–11) 4.0 (0–11) 1.0 (0–7)
PMS (UC, n=73), median (range) 1.0 (0–9) 3.0 (0–9) 0.0 (0–4)
Disease duration (years), mean ± SD 5.2±4.1 5.6±4.5 5.5±4.4 0.916
Age of diagnosis, years (CD, n=146), n (%) 0.606
 A1 (≤16) 6 (4.1) 3 (3.9) 3 (4.3)
 A2 (17–40) 125 (85.6) 67 (88.2) 58 (82.9)
 A3 (>40) 15 (10.3) 6 (7.9) 9 (12.9)
Location (CD, n=146), n (%) 0.574
 L1 (ileal) 16 (11) 10 (13.2) 6 (8.6)
 L2 (colonic) 11 (7.6) 4 (5.3) 7 (10.0)
 L3 (ileocolonic) 98 (67.1) 52 (68.4) 46 (65.7)
 L4 (upper GI tract) 21 (14.4) 10 (13.2) 11 (15.7)
Behavior (CD, n=146), n (%) 0.910
 B1 (inflammatory) 62 (42.5) 31 (40.8) 31 (44.3)
 B2 (stricturing) 47 (32.2) 25 (32.9) 22 (31.4)
 B3 (penetrating) 37 (25.3) 20 (26.3) 17 (24.3)
Perianal disease (CD, n=146), n (%) 0.692
 No 102 (69.9) 52 (68.4) 50 (71.4)
 Yes 44 (30.1) 24 (31.6) 20 (28.6)
Extent of colitis (UC, n=73), n (%) 0.161
 E1 (proctitis) 10 (13.7) 2 (5.7) 8 (21.1)
 E2 (left side) 30 (41.1) 16 (45.7) 14 (36.8)
 E3 (pancolitis) 33 (45.2) 17 (48.6) 16 (42.1)
Treatment, n (%) 0.011
 No treatment 11 (5.0) 7 (6.3) 4 (3.7)
 Mesalazine 19 (8.7) 14 (12.6) 5 (4.6)
 Steroid 18 (8.2) 14 (12.6) 4 (3.7)
 Immunosuppressive 110 (50.2) 47 (42.3) 63 (58.3)
 Biologics 61 (27.9) 29 (26.1) 32 (29.6)
Relapses of IBD in last year, n (%) 75 (34.2) 50 (45.0) 25 (23.1) 0.001
Hospitalizations for IBD in last year, n (%) 85 (38.8) 54 (48.6) 31 (28.7) 0.002
History of surgical resection, n (%) 50 (22.8) 28 (25.2) 22 (20.4) 0.392

Abbreviations: HRQOL, health-related quality of life; CD, Crohn’s disease; HBI, Harvey and Bradshaw Index; PMS, partial Mayo score; UC, ulcerative colitis; GI, gastrointestinal; IBD, inflammatory bowel disease.